The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -3,287,917 | -2,455,630 | -2,972,410 | -7,171,529 |
| Depreciation and amortization | 5,428 | 5,429 | 5,429 | 10,857 |
| Stock-based compensation | 101,068 | 109,024 | 113,754 | 255,363 |
| Issuance of common stock to consultants | - | 39,050 | - | - |
| Foreign currency (gain) loss | 7,711 | -8,701 | -5,691 | -80,927 |
| Prepaid expenses and other current and noncurrent assets | -181,777 | 735,651 | -169,996 | -347,749 |
| Accounts payable | 32,525 | 68,924 | -554,020 | -161,605 |
| Accrued expenses | 218,104 | -1,139 | 60,330 | -123,679 |
| Net cash used in operating activities | -2,756,726 | -2,961,292 | -3,171,230 | -6,761,917 |
| Proceeds from the exercise of warrants | - | 91 | - | - |
| Proceeds from issuance of common stock | 35,098,813 | 4,213,209 | 375,378 | 459,019 |
| Common stock issuance costs | 474,664 | 371,730 | 17,438 | 18,291 |
| Net cash provided by financing activities | 34,624,149 | 3,841,570 | 357,940 | 440,728 |
| Change in cash, cash equivalents and restricted cash | 31,867,423 | 880,278 | -2,813,290 | -6,321,189 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | -348 | 1,273 | 3,406 | - |
| Cash, cash equivalents and restricted cash-beginning of year | 14,640,533 | 9,131,073 | 22,890,055 | - |
| Cash, cash equivalents and restricted cash-end of period | 46,507,608 | 881,551 | 13,758,982 | - |
Aprea Therapeutics, Inc. (APRE)
Aprea Therapeutics, Inc. (APRE)